Hydrocortisone for COVID-19 and Severe Hypoxia

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 17, 2020

Primary Completion Date

September 10, 2020

Study Completion Date

September 8, 2021

Conditions
Covid-19Hypoxia
Interventions
DRUG

Hydrocortisone

Continuous infusion: 200 mg (104 ml) every 24 hours, Bolus injections: 50 mg (10 ml) every 6 hours, Total treatment duration: 7 days

DRUG

Sodium Chloride 9mg/mL

Continuous infusion: 104 ml every 24 hours, Bolus injections: 10 ml every 6 hours, Total treatment duration: 7 days

Trial Locations (14)

Unknown

Aarhus University Hospital - Dept of Intensive care, Aarhus

Dept of Infectious diseases, Rigshospitalet, Copenhagen

Herlev Hospital - Dept. of Intensive Care, Herlev

North Zealand Hospital, Hillerød

Hvidovre Hospital - Dept of Infectious diseases, Hvidovre

Hvidovre Hospital - Dept of Intensive Care, Hvidovre

Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre

Kolding Hospital, Kolding

Køge Hospital, Køge

Dept of Intensive Care, Odense University Hospital, Odense

Roskilde Hospital, Roskilde

Slagelse Hospital, Slagelse

Viborg Hospital, Viborg

DK-2100

Rigshospitalet, Copenhagen

All Listed Sponsors
collaborator

Rigshospitalet, Denmark

OTHER

collaborator

Copenhagen Trial Unit, Center for Clinical Intervention Research

OTHER

collaborator

University of Copenhagen

OTHER

collaborator

Aarhus University Hospital

OTHER

lead

Scandinavian Critical Care Trials Group

OTHER

NCT04348305 - Hydrocortisone for COVID-19 and Severe Hypoxia | Biotech Hunter | Biotech Hunter